First human tests begin for potential Alpha-1 treatment
Disease control
Completed
This early-stage study tested the safety and how the body processes WVE-006, a potential new treatment for Alpha-1 antitrypsin deficiency. It involved 47 healthy volunteers who received either the drug or a placebo. The goal was to find safe dose levels to use in future studies w…
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC